GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Other Current Liabilities

NRX Pharmaceuticals (STU:B1Q) Other Current Liabilities : €4.44 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Other Current Liabilities?

NRX Pharmaceuticals's other current liabilities for the quarter that ended in Jun. 2024 was €4.44 Mil.

NRX Pharmaceuticals's quarterly other current liabilities increased from Dec. 2023 (€0.02 Mil) to Mar. 2024 (€0.02 Mil) and increased from Mar. 2024 (€0.02 Mil) to Jun. 2024 (€4.44 Mil).

NRX Pharmaceuticals's annual other current liabilities declined from Dec. 2021 (€4.31 Mil) to Dec. 2022 (€0.03 Mil) and declined from Dec. 2022 (€0.03 Mil) to Dec. 2023 (€0.02 Mil).


NRX Pharmaceuticals Other Current Liabilities Historical Data

The historical data trend for NRX Pharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Other Current Liabilities Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Other Current Liabilities
- - - -

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NRX Pharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.


NRX Pharmaceuticals Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


NRX Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals Headlines

No Headlines